Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Companyâs main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļADAG
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAdagene Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 09, 2021
āļāļĩāļāļĩāđāļLuo (Peter)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ138
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒDepository Receipt
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 09
āļāļĩāđāļāļĒāļđāđ4F, Building C14, No. 218, Xinghu Street
āđāļĄāļ·āļāļSUZHOU
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻChina
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ8651287773632
āđāļ§āđāļāđāļāļāđhttps://www.adagene.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļADAG
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 09, 2021
āļāļĩāļāļĩāđāļLuo (Peter)
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
Mr. Cheung (Yiu Leung) Andy
Mr. Cheung (Yiu Leung) Andy
Independent Director
Ms. Yuwen Liu
Independent Director
Dr. Li Min, Ph.D.
Independent Director
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream